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We present a case of reactive amyloidosis that developed secondary to common variable immunodeficiency and rheumatoid
arthritis. A 66-year-old woman, with prior history of common variable immunodeficiency and rheumatoid arthritis, was referred to
our clinic for chronic diarrhea investigation.The patient was submitted to colonoscopy with ileoscopy, which did not show relevant
endoscopic alterations. However, undertaken biopsies revealed amyloid deposition. Since amyloidosis with GI involvement is a rare
cause of chronic diarrhea, this pathology should be considered in etiologic investigation, especially when associated with chronic
inflammatory diseases.
1. Introduction
Amyloidosis is a rare disease resulting from extracellular
deposition of insoluble fibrillar proteins, subclassified as
primary when fibrils result frommonoclonal light chain frag-
ments deposition and as secondary when the accumulated
material is serum amyloid A [1]. In the past, the main cause
for AA amyloidosis was chronic infectious diseases, such
as tuberculosis. Nowadays, 50% of cases are due to chronic
inflammatory diseases, with rheumatoid arthritis (RA) being
the most frequent one, followed by ankylosing spondylitis
and psoriatic arthritis [2].
In secondary subclassification, amyloidosis histological
gastrointestinal (GI) involvement is very common, although
clinically overt disease is rare [2]. On the contrary, in primary
amyloidosis GI involvement occurs less frequently, once only
8% have amyloid tissue infiltration and 1% of patients have GI
symptoms [3].
We report an unusual case of intestinal AA amyloidosis
in a patient with common variable immunodeficiency and
rheumatoid arthritis.
2. Case Report
A 66-year-old female with history of pleuropulmonary
tuberculosis in 1979 and a thymoma in 2006 was submitted
to resection and adjuvant radiotherapy. Since 2006, the
patient has been investigated for recurrent respiratory tract
infection. According to the complementary investigation
conducted, our patient was submitted to a chest computed
tomography, which showed bilateral interstitial thickening
and bronchiectasis in the right hemithorax (Figure 1), leading
to the conclusion of being radiation pneumonitis.
Also in 2006, she was referred to Rheumatology clinics
for arthritis and rheumatoid factor and antinuclear antibody
positives. Laboratory studies revealed the following: high
serum value of C-reactive protein (CRP) 22mg/dL (normal
range: <0.1) and decreased immunoglobulins, IgG 593mg/dL
(normal range: 700–1000), IgA 40mg/dL (normal range:
70–400), and IgM 8mg/dL (normal range: 40–230). After
exclusion of other rheumatic conditions, the diagnosis of
rheumatoid arthritis was assumed. Due to high articular
activity, immunomodulation was introduced starting with
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Figure 1: Chest computed tomography: bilateral interstitial thick-
ening and bronchiectasis in the right hemithorax.
increasing doses of sulphasalazine, up to 3 g per day (patient
refused methotrexate), hydroxychloroquine, naproxen up
to 1000mg per day, deflazacort 6mg/day, alendronic acid
70mg/week, and calcium, resulting in partial improvement of
arthritis. She was referred to Hematology that confirmed the
diagnosis as Common Variable Immunodeficiency, initiating
a monthly treatment with intravenous human immunoglob-
ulin.
Two years after the diagnosis, the patient had worsened
articular activity and developedwatery diarrhea, with average
stools frequency of up to 4 to 5 times a day with no
blood, mucus, or pus, along with intermittent abdominal
pain. She denied fever, hematic losses, anorexia, weight loss,
and profuse sweating. Abdominal physical examination was
unremarkable and laboratory findings revealed the following:
no anemia, thrombocytosis of 487000 platelets/L (normal
values: 120–44000), erythrocyte sedimentation rate (ESR)
28mm/h (normal value: 0–15), and 3.6mg/dL of CRP.Micro-
biologic and parasitological analyses of the stools were neg-
ative. HIV and anti-CMV IgM serologies were negative. The
colonoscopy with ileoscopy showed an accentuated vascular
pattern along the colon, with no other significant changes.
Biopsieswere obtained fromdifferent colon segments.Micro-
scopically, deposition of amorphous hyaline material that
infiltrated the submucosa wall in colon with hematoxylin-
eosin was observed. Congo red staining allowed detection of
green birefringence on fibrils (Figure 2). Immunohistochem-
istry showed marking of AA proteins, confirming a reactive
amyloidosis (Figures 3 and 4). Additional investigation was
performed having excluded renal involvement by amyloido-
sis, with no changes in proteinuria and creatinine clearance.
The patient became asymptomatic after controlling RA
activity with the addition of Tocilizumab, a biologic agent
(TB reactivation excluded: chest CT, bronchofiberscopy, and
cultures), and has been kept under surveillance without GI
symptoms.
3. Discussion
Common variable immunodeficiency (CVID) is the most
symptomatic primary antibody deficiency, characterized by
hypogammaglobulinemia, leading primarily to recurrent
Figure 2: Perivascular amyloid deposit in colon submucosa (Congo
red staining without polarization).
Figure 3: Perivascular amyloid deposit in colon submucosa (Congo
red staining, with polarization).
pulmonary orGI infections [4]. Such as in our case, where the
patient had recurrent pulmonary infection after treatment for
thymoma, these complications may be present at the onset or
may appear later.
In about 20% of the cases, common variable immunode-
ficiency is also associated with autoimmune diseases, such as
rheumatoid arthritis [5]. In our case, the RA diagnostic was
established simultaneously with CVID.While the pathogene-
sis of autoreactivity is unknown for CVID subjects in general,
and to a greater extent for those with autoimmunity, there is
a loss of switched memory B cells [5].
The incidence of gastrointestinal diseases in CVID group
has a considerable relevance, referred to be between 20 and
60%, with the chronic diarrhea being the most common
presentation of this disease [6]. Between 6 and 10% of CVID
patients develop inflammatory bowel disease-like disorder
and a poor group develop celiac enteropathy like lymphoma,
gastric adenocarcinoma, and intestinal amyloidosis. The
alterations on immune mediators such as impaired antibody
production, disruption on T-cell function, and defects in
innate immunity could be responsible forGI disease observed
in CVID patients [6]. The secondary amyloidosis is a rather
rare complication of the CVID; a time frame of 8 to 14
years between the AA amyloidosis diagnostic and the CVID
inflammatory condition is seldom observed [7]. All amyloi-
dosis CVID cases have recurrent infections, which was also
observed in our patient, consisting in a relevant condition
supposed to be related to amyloidosis progression [7]. The
intravenous immunoglobulin administration decreased our
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Figure 4: Immunolabeling pattern with monoclonal anti-amyloid
A antibody (mc1 clone).
patient’s episodes of pulmonary infections but not the GI
symptoms.
Recently, LRP12 mutations were found in patients with
intestinal amyloidosis and CVID, which denotes the complex
association between immunodeficiency and autoinflamma-
tory disease [8].
Rheumatoid arthritis can either be associated with CVID
or be an independent condition for amyloidosis development,
which was not possible to determine in our case. Nowadays,
RA is known to be one of the most common causes of
AA amyloidosis, with a prevalence between 10 and 29% of
patients with such disorder, varying according to different
previous studies [9], usually associated with long duration
(7 to 10 years) and uncontrolled rheumatoid arthritis. Our
patient had a short duration and nonerosive arthritis at
amyloidosis diagnosis, which however could have been a
subclinical disease. Rheumatoid arthritis therapeutics aims
to achieve disease remission by suppressing inflammation
and immunological dysregulation [10]. Sulphasalazine was
initially chosen instead of methotrexate, either due to the
patient’s refusal of that drug or due to the potentially limiting
pulmonary drug toxicity. However, articular inflammatory
activity was recurrently observed, requiring a more potent
therapeutic approach.
Due to the history of pulmonary tuberculosis and
immunomodulator therapy, mycobacterium intestinal infec-
tion should be excluded. The patient did not present clinical
evidence of pulmonary tuberculosis and had normal chest
X-ray. However, 76% of intestinal tuberculosis cases may
occur in asymptomatic patients. The absence of granuloma
or alcohol-acid-resistant bacilli at colonic biopsy leads to
disregarding such hypothesis [11].
Independently of the trigger for secondary AA, there
are unspecific gastrointestinal symptoms, varying from gas-
trointestinal haemorrhage to chronic intestinal dysmotility,
or malabsorption caused by colon mucosa infiltration and
bacterial overgrowth, or even exudative gastroenteropathy. Its
endoscopic appearance derives from colon mucosa infiltra-
tion, more frequent at the descendent duodenum followed
by stomach, colon, and esophagus. Intestinal mucosa may
present itself slightly granular and friable erosions, ulcera-
tions, and submucosa hematomas; nevertheless, polypoid or
nodular lesions can rarely occur [1, 12]. Intestinal biopsies are
diagnostic ofAAamyloidosis in 75–95%of cases and it should
be performed even in the presence of normal appearing
mucosa [13].
Several studies have focused on genetic factors, with
prognostic significance, which might increase susceptibility
to AA, aiming to identify patients that would benefit from
more aggressive treatments. To date, SAAgenotype is the only
established variable that significantly affects the risk of AA
development. SSA genotype was not evaluated in our patient
[14].
The aim of symptomatic treatment is to control the
underlying disease. In cases of severe diarrhea and exuda-
tive gastroenteropathy, the use of steroids, octreotide, or
immunosuppressors should be considered [14].
Our patient had two pathologic entities that can be
associated with amyloidosis, common variable immunode-
ficiency and rheumatoid arthritis, both contributing to the
development of intestinal amyloidosis. The perception of
which pathology had a more significant contribution to
amyloid substances intestinal deposition was unachievable.
However, the previous history of pulmonary tuberculosis,
along with recurrent pulmonary infections during the course
of CVID and the CVID itself which led to RA development,
may be in the origin of the amyloid deposition.
In conclusion, when investigating unknown etiology
of chronic diarrhea, associated with chronic inflammatory
disease, the biopsies are essentials, permitting the diagnosis of
rare intestinal amyloidosis, allowing a clinical and therapeutic
estimate, and significantly contributing to patient’s quality of
life.
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